Drug Delivery Business

Bigfoot Biomedical raises $55m in Series C

By

Bigfoot Biomedical updated logoDiabetes treatment tech company Bigfoot Biomedical announced today that it raised $55 million to close its Series C financing round.

Abbott (NYSE:ABT) led the funding round with participation from new investor Smile Group and existing investors Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management.

Get the full story at our sister site, MassDevice.

IN CASE YOU MISSED IT

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.